| Identification | Back Directory | [Name]
Rivipansel Sodium | [CAS]
927881-99-0 | [Synonyms]
PF-06460031)
Rivipansel Sodium
GMI-1070
(Rivipansel
1,3,6-Naphthalenetrisulfonic acid, 8-[[13-[(1R,3R,4R,5S)-3-[[2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexylethyl]-β-D-galactopyranosyl]oxy]-4-[(6-deoxy-α-L-galactopyranosyl)oxy]-5-[[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]amino]cyclohexyl]-1,8,13-trioxo-3,6-dioxa-9,12-diazatridec-1-yl]ami... | [Molecular Formula]
C58H74N6O31S3 | [MOL File]
927881-99-0.mol | [Molecular Weight]
1447.42 |
| Hazard Information | Back Directory | [Uses]
Rivipansel (GMI-1070) is a potent E-selectin antagonist. Rivipansel prevents interaction between leukocytes and vascular endothelium. Rivipansel has the potential for the research of sickle cell vaso-occlusive crisis[1][2]. | [References]
[1] Dampier CD, et al. A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC). Blood. 2022 Aug 18:blood.2022015797. DOI:10.1182/blood.2022015797
[2] Carlton D.DampierMD, et al. Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136 (1):18-19. |
|
|